Walgreens Launches Patient Advisory Board to Enhance Clinical Trial Diversity
• Walgreens has formed a Clinical Trials Patient Advisory Board to improve patient recruitment and retention in clinical trials.
• The initiative focuses on increasing representation from historically underrepresented communities in clinical research.
• Since June 2022, Walgreens' Clinical Trials team has engaged over 7 million patients for potential trial participation.
• The advisory board consists of 10 patient experts serving 2-year terms to provide ongoing counsel and diverse perspectives.
Walgreens Expands Clinical Trial Capabilities, Focusing on Diversity and Accessibility
• Walgreens is leveraging its pharmacy network to enhance patient recruitment and real-world evidence services for biopharma, emphasizing improved access and representation in clinical trials.
• The company's clinical trial business model centers on insights-driven patient recruitment, flexible trial conduct options (in-store, hybrid, at-home), and real-world evidence informatics.
• Walgreens is actively working across various therapeutic areas, including diagnostic screenings for lung and colon cancer, diabetes, cardiovascular outcomes, and vaccination programs.
• Strategic partnerships, including collaborations with BARDA and Boehringer Ingelheim, are aimed at decentralizing clinical trials and reaching underserved communities, highlighting Walgreens' commitment to inclusive research.
© Copyright 2025. All Rights Reserved by MedPath